Obesity: key endpoint results by drug

The key endpoints of Obesity trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Obesity page.

Body weight, % change

Body weight, % change in Obesity: 17 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
ARD-101-0.3%0.4%−0.7wk 4 · n 14NCT05121441 Phase 2, primary
cagrilintide-10.8%-3%−7.84.5 mg · wk 26 · n 97NCT03856047 Phase 2, primary
cagrilintide/semaglutide-13.7%a-3.4%−10.3wk 68NCT05394519 Phase 3, primary
ecnoglutide-13.2%a0.1%−13.3ecnoglutide 2.4 mg · wk 40NCT05813795 Phase 3, primary
efpeglenatide-9.8%a-0.9%−8.8wk 40NCT06174779 Phase 3, primary
eloralintide-20.1%-0.4%−19.79 mg · wk 48 · n 54NCT06230523 Phase 2, primary
mazdutide-7.3%-0.8%−6.53/6 mg · wk 32 · n 32NCT06124807 Phase 2, primary
metreleptin-6.4%-2.0%−4.4360 mcg + 1.25 mg · wk 28 · n 45NCT00673387 Phase 2, primary
naltrexone/bupropion-7.7%-6.5%−1.2wk 12 · n 93NCT03374956 Phase 3, primary
orforglipron-7.9%-0.6%−7.336 mg QD · wk 72 · n 60NCT05931380 Phase 3, primary
pemvidutide-15.6%a-2.2%−13.42.4mg · wk 48NCT05295875 Phase 2, primary
phentermine/topiramate-7.8%-1.2%−6.6wk 56 · n 488NCT00553787 Phase 3, primary
pramlintide-5.5%-2.0%−3.5360 mcg · wk 28 · n 51NCT00673387 Phase 2, primary
retatrutide-17.4%-1.6%−15.812 mg (2 mg) · wk 24 · n 62NCT04881760 Phase 2, primary
setmelanotide0.4%-0.4%+0.82.5 mg · wk 6 · n 9NCT02311673 Phase 2, primary
survodutide-14.9%-2.8%−12.14.8 mg · wk 46 · n 76NCT04667377 Phase 2, primary
zovaglutide-13.8%a-2.4%−11.4160mg monthly · wk 24NCT07020884 Phase 2, primary

Drugs checked with no result here: 11 not posted, 10 not reported, 18 trial running.

Weight loss of 5% or more

Weight loss of 5% or more in Obesity: 8 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
cagrilintide88.7%30.9%+57.84.5 mg · wk 26 · n 80NCT03856047 Phase 2, secondary
eloralintide92.7%31.2%+61.59 mg · wk 48 · n 54NCT06230523 Phase 2, secondary
mazdutide74.8%26.0%+48.83/6 mg · wk 48 · n 32NCT06124807 Phase 2, secondary
orforglipron58.3%15%+43.336 mg QD · wk 72 · n 60NCT05931380 Phase 3, primary
phentermine/topiramate62.1%20.8%+41.3wk 56 · n 488NCT00553787 Phase 3, primary
retatrutide100%27%+7312 mg (2 mg) · wk 48 · n 62NCT04881760 Phase 2, secondary
setmelanotide9.1%5.6%+3.5wk 12.857 · n 33NCT01749137 Phase 2, secondary
survodutide82.8%25.9%+56.94.8 mg · wk 46 · n 64NCT04667377 Phase 2, secondary

Drugs checked with no result here: 14 not posted, 15 not reported, 19 trial running.

Weight loss of 10% or more

Weight loss of 10% or more in Obesity: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
cagrilintide53.5%10.4%+43.14.5 mg · wk 26 · n 80NCT03856047 Phase 2, secondary
eloralintide82.3%12.8%+69.59 mg · wk 48 · n 54NCT06230523 Phase 2, secondary
mazdutide57.9%13.8%+44.13/6 mg · wk 48 · n 32NCT06124807 Phase 2, secondary
orforglipron38.3%3.3%+3536 mg QD · wk 72 · n 60NCT05931380 Phase 3, secondary
retatrutide93%9%+8412 mg (2 mg) · wk 48 · n 62NCT04881760 Phase 2, secondary
survodutide68.8%11.1%+57.74.8 mg · wk 46 · n 64NCT04667377 Phase 2, secondary

Drugs checked with no result here: 15 not posted, 16 not reported, 19 trial running.

Waist circumference, change (cm)

Waist circumference, change (cm) in Obesity: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
ARD-101-0.2-0.8+0.6wk 4 · n 14NCT05121441 Phase 2, secondary
bimagrumab-90.5−9.410 mg/kg · wk 52 · n 36NCT03005288 Phase 2, secondary
cagrilintide-9.5-3.4−6.14.5 mg · wk 26 · n 97NCT03856047 Phase 2, secondary
metreleptin-4.7-2.5−2.2360 mcg + 1.25 mg · wk 28 · n 45NCT00673387 Phase 2, secondary
orforglipron-5.7-0.1−5.636 mg QD · wk 72 · n 60NCT05931380 Phase 3, secondary
phentermine/topiramate-5.00.6−5.6wk 56 · n 54NCT03922945 Phase 4, secondary
pramlintide-4.0-2.5−1.4360 mcg · wk 28 · n 51NCT00673387 Phase 2, secondary
retatrutide-19.6-2.6−1712 mg (2 mg) · wk 48 · n 62NCT04881760 Phase 2, secondary
survodutide-16.0-4.0−124.8 mg · wk 46 · n 75NCT04667377 Phase 2, secondary

Drugs checked with no result here: 16 not posted, 11 not reported, 20 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 56 approved or late-stage drugs with a featured trial in Obesity were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.